Arpeggio Bio
Arpeggio Bio is a preclinical-stage biotech using an AI-enabled transcriptomic screening platform to discover small-molecule therapeutics targeting transcription factors, with an initial pipeline focus on lung cancer.
- Company typePrivate
- Founded2017
- HeadquartersBoulder, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Arpeggio Bio does
Arpeggio Bio (legal name: Arpeggio Bioscience Inc.) is a preclinical-stage pharmaceutical company founded in 2017 and headquartered at 4888 Pearl East Circle, Suite 110E in Boulder, Colorado. The company develops an AI-enabled drug discovery platform that combines functional genomics, biological assays, and machine learning to analyze how drugs affect cellular transcriptomes, with the explicit goal of targeting transcription factors that have historically been considered undruggable. Its core products are a proprietary transcription-monitoring technology platform and a preclinical drug pipeline focused initially on lung cancer and broader cancers driven by transcriptional dysregulation, including programs centered on NRF2 and transcriptional addiction mechanisms such as CDK7 inhibition.
The platform's technical architecture uses biological assays to perturb cells with drug candidates and then applies machine learning to RNA expression readouts, enabling systematic discovery of therapeutic targets and characterization of drug function at the transcriptome level. This capability is intended to overcome a long-standing limitation in oncology drug discovery: transcription factors regulate gene expression programs underlying many cancers but have resisted traditional small-molecule approaches. Arpeggio's founding team includes CEO Joey Azofeifa, PhD in Computer Science from the University of Colorado, whose graduate work at the AI-cancer genomics intersection produced the founding IP, and co-founder Tim Read, PhD in Molecular Biology, who leads discovery biology efforts.
The business model is preclinical-stage R&D with no commercialized products, no disclosed pricing, and no revenue-generating customers at present. The company has raised over $60 million cumulatively across multiple rounds (including a $17 million Series A led by Builders VC in September 2022 and a $20 million round in November 2025) from institutional life-sciences investors including Khosla Ventures, Tencent, Westlake BioPartners, venBio, and Y Combinator. Go-to-market will ultimately depend on internal clinical development, out-licensing of pipeline assets, or partnerships with larger pharmaceutical companies, none of which have been disclosed to date.
Arpeggio Bio firmographics
Firmographics- Name
- Arpeggio Bio
- Legal name
- Arpeggio Bioscience Inc.
- Website
- https://arpeggiobio.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Arpeggio Bio is a preclinical-stage biotech using an AI-enabled transcriptomic screening platform to discover small-molecule therapeutics targeting transcription factors, with an initial pipeline focus on lung cancer.
- Ownership category
- akta.pro rank
Arpeggio Bio industry classification
Industry- Product category
- Drug Discovery
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro industry
- High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
Keywords
Where Arpeggio Bio is headquartered
LocationHeadquarters
- HQ city
- Boulder
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Arpeggio Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Marketing channels1 record
Arpeggio Bio product offering
Product offeringCore offering
Arpeggio Bio is a preclinical-stage pharmaceutical company developing an AI-enabled transcription-monitoring platform that combines functional genomics, biological assays, and machine learning to measure how drugs affect cellular transcriptomes. The company uses this platform to discover and advance drug candidates against historically 'undruggable' transcription factors that drive hard-to-treat diseases, with an initial focus on lung cancer.
Product overview
Arpeggio Bio is a preclinical-stage pharmaceutical company developing a drug discovery platform that combines functional genomics with machine learning to analyze how drugs affect cellular transcriptomes. The company's core technology is its transcription-monitoring platform, which uses biological assays and AI to measure drug effects on RNA expression patterns, specifically targeting difficult-to-drug transcription factors. The company is applying this platform to discover and develop therapies for cancer and other diseases caused by transcriptional dysregulation, with a focus on lung cancer and undruggable transcription factor targets.
Differentiator
Problem solved
Functional benefit
Products and services
- Transcription-Monitoring Technology Platform Proprietary AI-enabled platform that measures the effects of drugs on cellular transcriptomes by combining biological assays with machine learning. Used internally to discover and validate therapeutic targets, including historically difficult-to-drug transcription factors, in diseases such as cancer.
- Drug Pipeline for Transcription Factor Targets Preclinical-stage pipeline of therapeutic candidates targeting transcription factors and transcriptional addiction mechanisms in cancer, with programs including NRF2 and other lung cancer targets. Currently in preclinical development with no commercialized products.
Companies that use Arpeggio Bio
Customer profileSegments1 record
Ideal customer profiles1 record
Arpeggio Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Arpeggio Bio partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights4 records
Arpeggio Bio competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: Clinical-stage AI-driven drug discovery company combining high-throughput biology with machine learning. Like Arpeggio, Recursion uses functional/phenotypic screening at scale to identify novel therapeutic targets, including historically difficult ones.
- Insitro: Machine learning-driven drug discovery company that combines high-throughput biology with AI/ML to identify targets and develop therapeutics. Directly comparable to Arpeggio in applying AI/ML to functional genomics for novel target identification.
- Schrödinger: Computational chemistry and AI-driven drug discovery platform company serving both internal pipeline and external pharma collaborators. Comparable to Arpeggio in leveraging computational methods to address difficult-to-drug targets.
- Exscientia: AI-driven precision medicine and drug discovery company with clinical-stage assets. Comparable to Arpeggio in using AI to design and prioritize drug candidates, including against challenging target classes.
- Atomwise: AI-driven small molecule drug discovery company using structure-based deep learning models. Comparable to Arpeggio in pursuing AI-enabled approaches to drug historically difficult targets, with active pharma partnerships.
- Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind's protein structure prediction and computational biology to drug discovery. Comparable to Arpeggio in leveraging AI to tackle targets (including transcription factors and protein-protein interactions) historically resistant to small-molecule approaches.
Emerging players
- Generate Biomedicines: Flagship Pioneering-founded AI/generative biology company designing novel protein therapeutics. Comparable to Arpeggio in applying ML to biology for novel therapeutic generation against difficult targets.
- XtalPi: AI-driven drug discovery company combining physics-based modeling with ML for small molecule design. Comparable to Arpeggio in using AI/ML for computational drug design across difficult target classes.
- Syros Pharmaceuticals: Clinical-stage biopharma focused on gene regulation and transcriptional dysregulation, including CDK7 inhibitors. Highly relevant comparable given Arpeggio Senior Scientist Jenna Rimel's prior collaboration with Syros on CDK7 inhibitors and overlapping transcription factor targeting space.
- Forma Therapeutics: Biopharmaceutical company targeting rare hematologic diseases and cancers, including transcription factor and protein-protein interaction targets. Comparable given CEO Joey Azofeifa's prior role at Forma, and overlapping focus on difficult oncology targets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Arpeggio Bio social profiles
Digital presenceArpeggio Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arpeggio Bio leadership team
Management profileNumber of profiles
Profiles14 records
Arpeggio Bio funding detail
Funding detailFunding overview
Funding rounds5 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arpeggio Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arpeggio Bio
What does Arpeggio Bio do?
Arpeggio Bio is a preclinical-stage pharmaceutical company developing an AI-enabled transcription-monitoring platform that combines functional genomics, biological assays, and machine learning to measure how drugs affect cellular transcriptomes. The company uses this platform to discover and advance drug candidates against historically 'undruggable' transcription factors that drive hard-to-treat diseases, with an initial focus on lung cancer.
Is Arpeggio Bio a public or private company?
Arpeggio Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Arpeggio Bio founded?
Arpeggio Bio was founded in 2017. It employs 1 to 10 people.
Where is Arpeggio Bio based?
Arpeggio Bio is headquartered in Boulder, United States, in the North America region.
Who are Arpeggio Bio's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Insitro, Schrödinger, Exscientia, Atomwise and Isomorphic Labs. Emerging players are Generate Biomedicines, XtalPi, Syros Pharmaceuticals and Forma Therapeutics.
Does Arpeggio Bio have an API?
No public API is recorded for Arpeggio Bio.
What industry is Arpeggio Bio in?
Arpeggio Bio's product category is Drug Discovery. Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 334516 and its SIC code is 3826.